Research location
Dnipro
Ukraine
Advertisement
Research activity in Dnipro
UkraineCureCurrent currently publishes aggregate city-level research activity for this location: 248 trials and 294 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Dnipro
248 linked trials · page 1 of 5Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate AsthmaNCT07301736 · 2025-12-17 · 1 site observation
RECRUITING
An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab TreatmentNCT06675955 · 2024-12-13 · 1 site observation
RECRUITING
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)NCT06452277 · 2024-08-28 · 1 site observation
RECRUITING
A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other OptionNCT05179876 · 2022-05-04 · 1 site observation
RECRUITING
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.NCT06372145 · 2024-04-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 MutationsNCT05904730 · 2023-07-11 · 1 site observation
COMPLETED
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) StudiesNCT05226871 · 2022-07-07 · 1 site observation
ACTIVE_NOT_RECRUITING
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)NCT05259033 · 2022-04-11 · 1 site observation
COMPLETED
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisNCT05201638 · 2022-01-12 · 4 site observations
ACTIVE_NOT_RECRUITING
Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients with Levodopa Induced DyskinesiaNCT05297201 · 2021-11-02 · 1 site observation
COMPLETED
Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast CancerNCT04869943 · 2021-10-12 · 1 site observation
TERMINATED
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple SclerosisNCT05054140 · 2021-09-30 · 2 site observations
UNKNOWN
Study of INCB086550 in Select Solid TumorsNCT04629339 · 2021-09-02 · 1 site observation
TERMINATED
A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)NCT04636801 · 2021-07-14 · 2 site observations
TERMINATED
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)NCT04636814 · 2021-07-12 · 1 site observation
TERMINATED
Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple SclerosisNCT04879628 · 2021-06-07 · 2 site observations
ACTIVE_NOT_RECRUITING
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)NCT04799249 · 2021-05-14 · 1 site observation
COMPLETED
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPCNCT04821622 · 2021-05-12 · 2 site observations
ACTIVE_NOT_RECRUITING
A Study of Selexipag in Participants Who Participated in a Previous Selexipag StudyNCT04565990 · 2021-05-03 · 1 site observation
COMPLETED
A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)NCT04738123 · 2021-04-06 · 1 site observation
COMPLETED
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)NCT04586010 · 2021-03-17 · 1 site observation
ACTIVE_NOT_RECRUITING
A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily InsulinNCT04770532 · 2021-03-05 · 1 site observation
COMPLETED
A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple SclerosisNCT04711148 · 2021-03-01 · 3 site observations
UNKNOWN
Open-label Trial in Parkinson's Disease (PD)NCT04760769 · 2021-02-24 · 2 site observations
COMPLETED
Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate CancerNCT04736199 · 2021-02-23 · 1 site observation
COMPLETED
An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)NCT04659174 · 2021-02-01 · 1 site observation
COMPLETED
EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)NCT04509674 · 2020-12-16 · 1 site observation
COMPLETED
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)NCT04548999 · 2020-12-03 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)NCT04544436 · 2020-11-26 · 1 site observation
ACTIVE_NOT_RECRUITING
A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 DiabetesNCT04596631 · 2020-11-02 · 2 site observations
COMPLETED
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCNCT04446117 · 2020-10-19 · 2 site observations
ACTIVE_NOT_RECRUITING
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 InsertionsNCT04538664 · 2020-10-13 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney DiseaseNCT04492722 · 2020-10-01 · 2 site observations
TERMINATED
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT04487080 · 2020-09-30 · 1 site observation
ACTIVE_NOT_RECRUITING
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)NCT04411641 · 2020-09-24 · 1 site observation
COMPLETED
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)NCT04497844 · 2020-09-23 · 3 site observations
ACTIVE_NOT_RECRUITING
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)NCT04542499 · 2020-09-23 · 1 site observation
COMPLETED
Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%NCT04435626 · 2020-09-14 · 1 site observation
COMPLETED
Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung CancerNCT04205812 · 2020-09-11 · 1 site observation
COMPLETED
Study on the Safety of the Drug Runcaciguat and How Well it Works When Given at the Highest Dose as Tolerated by Individual Patient Whose Kidneys Are Not Working Properly and Suffering at the Same Time From High Blood Sugar and/or High Blood Pressure and a Disease of the Heart and the Blood Vessels.NCT04507061 · 2020-09-01 · 1 site observation
COMPLETED
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeNCT04408755 · 2020-07-13 · 1 site observation
TERMINATED
A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary HypertensionNCT04271475 · 2020-07-07 · 1 site observation
TERMINATED
Study of Evobrutinib in Participants With RMS (evolutionRMS 2)NCT04338061 · 2020-07-02 · 3 site observations
TERMINATED
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial HypertensionNCT04273945 · 2020-06-30 · 1 site observation
ACTIVE_NOT_RECRUITING
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)NCT04410991 · 2020-06-11 · 1 site observation
COMPLETED
Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced MalignanciesNCT04181788 · 2020-03-18 · 3 site observations
COMPLETED
Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)NCT04248829 · 2020-02-13 · 1 site observation
COMPLETED
A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial HypertensionNCT04175600 · 2020-01-16 · 2 site observations
ACTIVE_NOT_RECRUITING
A Study for the Identification of Biomarker Signatures for Early Detection of Pulmonary Hypertension (PH)NCT04193046 · 2019-12-16 · 1 site observation
COMPLETED
Fixed-Dose Trial in Early Parkinson's Disease (PD)NCT04201093 · 2019-12-13 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.